Key statistics dashboard for RenovoRx, Inc. (RNXT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc.
Stock Data
| Price | $1.55 |
| Market Cap | $70M |
| Beta | 1.22 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -5.44 |
| Price / Book | 9.06 |
| P/S | 39.22 |
| P/FCF | -6.49 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 84.41% |
| EBIT Margin | -621.76% |
| EBITDA Margin | -621.71% |
| Operating Margin | -678.04% |
| Net Margin | -621.71% |
Financial Health
| Current Ratio | 5.74 |
| Quick Ratio | 5.53 |
| Cash Ratio | 5.03 |
| Debt / Equity | 0.03 |
| Debt / Assets | 2.26% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -8.04 |
Per-Share Data
| Revenue per share | 0.04 |
| Book Value per share | 0.19 |
| Cash per share | 0.20 |
| FCF per share | -0.25 |
| Tangible Book Value per share | 0.19 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Related companies: ANVS · BCAB · CALC · CELU · ELUT · LTRN · MAIA
Explore sector: Healthcare · Biotechnology
More sections of RNXT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks